Omnicell, Inc. to Acquire Aesynt for $275 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Lower Revenues and Guidance on Omnicell (OMCL) Raises Concerns; Cowen Cuts Price Target to $29
October 30, 2015 8:24 AM EDTCowen maintained a Market Perform rating on Omnicell (NASDAQ: OMCL), and cut the price target to $29.00 (from $37.00), following the company's 3Q earnings results. OMCL reported 3Q adjusted EPS of $0.36, in-line with consensus expectations. Revenues slightly missed this quarter coming in at $125.2M, up 11.3%... More
Omnicell (OMCL) Reports In-Line Q3 EPS; Announces $275M Acquisition of Aesynt
October 29, 2015 4:38 PM EDTOmnicell (NASDAQ: OMCL) reported Q3 EPS of $0.36, in-line with the analyst estimate of $0.36. Revenue for the quarter came in at $125.2 million versus the consensus estimate of $128.54 million.
OMCL also announced it has entered into a definitive agreement to acquire Aesynt Incorporated. The acquisition would create the broadest product portfolio in the industry with significant offerings in automated dispensing systems, central pharmacy robotics, IV robotics and enterprise analytics. The combined company would support approximately 4,000 acute care facilities worldwide, have annual revenues of over $650 million and have approximately 2,200 employees.
"As hospitals... More
